MolMed S.p.A.
via Olgettina, 58
Milan
20132
Tel: 39-0221277-1
Fax: 39-0221277-220
Website: http://www.molmed.com/
Email: info@molmed.com
7 articles about MolMed S.p.A.
-
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration
7/9/2020
Orchard Therapeutics, a global gene therapy leader, and MolMed S.p.A, one of the company’s principal contract development and manufacturing partners, announced that they have extended their collaboration – initiated in April 2018 – for a period of five years through June 2025.
-
MolMed S.p.A. Signs an Agreement With GlaxoSmithKline to Develop a Production Process for a Gene Therapy
8/5/2011
-
MolMed S.p.A. Release: Results of three Phase II Trials in Lung Cancer Indications Confirm Safety and Antitumour Activity of NGR-hTNF
6/3/2011
-
FDA Grants Orphan Drug Designation for MolMed S.p.A.'s Investigational Antiumour Drug
8/29/2008
-
MolMed S.p.A. Key Preliminary Results of Phase II Trials Presented
5/30/2008
-
Immunicon Corporation And MolMed S.p.A. Enter Research And Laboratory Services Agreements
9/28/2006
-
Takara Bio And MolMed S.p.A. Announce That Phase I/II Clinical Trial Of HSV-TK Gene Therapy Delivers Positive Results
12/15/2005